JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: A literature review

  • 0Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Asian Journal of Surgery +

|

March 5, 2024

|

March 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Microvascular invasion (MVI) is a key predictor of early recurrence and poor prognosis in hepatocellular carcinoma (HCC) patients after hepatectomy. This review explores MVI predictors, its link to recurrence, and management strategies for MVI-positive HCC.

Area Of Science

  • Hepatobiliary Surgery
  • Surgical Oncology
  • Hepatocellular Carcinoma Research

Background

  • Hepatectomy is a primary treatment for hepatocellular carcinoma (HCC).
  • Early recurrence (within 2 years) affects one-third of HCC patients post-hepatectomy, significantly impacting prognosis.
  • Microvascular invasion (MVI) is a critical factor linked to early recurrence and poorer outcomes in HCC.

Purpose Of The Study

  • To review current literature on microvascular invasion (MVI) in HCC.
  • To summarize predictors of MVI and its correlation with early recurrence.
  • To explore diagnostic and therapeutic strategies for MVI-positive HCC.

Main Methods

  • Literature review of recent studies on MVI in HCC.
  • Analysis of predictors for MVI.
  • Examination of the relationship between MVI and early tumor recurrence.
  • Review of methods for identifying suspicious nodules and subclinical lesions.
  • Synthesis of treatment strategies for MVI-positive HCC.

Main Results

  • Microvascular invasion (MVI) is a significant predictor of early recurrence in HCC patients post-hepatectomy.
  • Identifying MVI aids in stratifying patients with higher risk of recurrence and poorer prognosis.
  • Early detection of MVI and associated subclinical lesions is crucial for effective management.

Conclusions

  • Management of MVI-positive HCC requires a comprehensive approach.
  • Understanding MVI predictors and its clinical impact is essential for improving patient outcomes.
  • Further research into targeted therapies for MVI-positive HCC is warranted.

Keywords: